PPT-ABSORB China : Two-Year Clinical

Results in Patients with Coronary Artery Disease Randomized to the Absorb Bioresorbable Vascular Scaffold Versus Metallic DrugEluting Stents Runlin Gao MD On behalf of ABSORB China Investigators. A clinical evaluation to compare the safety efficacy and performance of the Absorb everolimuseluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects wit The ABSORB III trial. Dean J. Kereiakes, MD, . Stephen . G. Ellis, MD, D. Christopher Metzger, MD, Ronald P. Caputo, MD, David G. Rizik, MD, Paul S. Teirstein, MD, Marc R. . Litt. , MD, . Annapoorna. clinico. in . tema. di BVS. Bernardo Cortese. Intv. ’ . Cardiology. , A.O. Fatebenefratelli. bcortese@gmail.com. b. ernardocortese.com. Bernardo Cortese MD FESC. A.O. Fatebenefratelli. The ABSORB Clinical Trial Program. CHINA IS A COMMUNIST COUNTRY.. ALL FAMILIES IN CHINA ARE LIMITED TO ONE CHILD.. GENERALLY SPEAKING, PARENTS HOPE TO HAVE BABY GIRLS, NOT BOYS.. CHINA’S OFFICAL RELIGION IS BUDDHISM.. MEN IN CHINA LOOKING TO GET MARRIED ARE VERY LUCKY BECAUSE THERE ARE A LOT MORE WOMEN, SO THEY HAVE A GOOD CHANCE OF FINDING THE WOMAN OF THEIR DREAMS.. Comparison of . Everolimus-­. Eluting . Absorb Bioresorbable Vascular. Scaffolds vs. . Everolimus-Eluting Metallic. . Stents:. One-Year Angiographic and Clinical Outcomes from the ABSORB China Trial. : . Two-Year Clinical . Results in Patients with Coronary Artery Disease Randomized to the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stents. Runlin . Gao, M.D.. On behalf of ABSORB China Investigators. trials“. Manish Narang. Sr. Medical Advisor-APJ, Abbott Vascular. 1. HAVING NOTHING . CAN MEAN EVERYTHING. 2. Why do we need a . bioresorbable scaffold?. LONG-TERM COMPLICATIONS OF PERMANENT STENTS. .. China . has the largest population in the world, . with a population of . over 1.3 billion . people. . China belongs to the continent of Asia. Bordering countries include Afghanistan, Nepal, Burma and India. Staff number grew from 1 to . 500+. 15+ Years of Strong Growth. 2004. 2008. 2014. 2015. 2001. 2015. 2012. Company Founded by Dr. Song Li . Opened Shanghai, China office. Began Phase I Clinical Operations . Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. Everolimus. Eluting . Bioresorbable. Vascular Scaffold and the XIENCE . Everolimus. Eluting Stent. Bernard Chevalier. Institut Jacques Cartier, Massy, France. Patrick W. Serruys. Imperial College, London, UK. Gregg W. Stone MD. Stephen G. Ellis MD and Dean J. Kereiakes MD. for the ABSORB IV Investigators. Disclosures. Chairman of the ABSORB global clinical trial program (uncompensated). Consultant to Reva, Inc.. vs. 1.46 mm, . p < 0.0001; . IVUS showed lower post-procedure mean lumen area in BVS arm (4.9 vs. 5.7 mm. 2. , . p < 0.001. ). 1-year scaffold thrombosis in . two . BVS . patients; . no stent thrombosis in DES arm. Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention. Gregg W. Stone, MD. On behalf of Akiko Maehara, Ziad A. Ali, Claes Held, . Mitsuaki. Matsumura, Lars . Kjøller.